AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
Use Of Esomeprazole In Postoperative Bariatric Surgery Patients Users And Non-Users Of Nonsteroidal Anti-Inflammatory Drugs (NSAIDS)
Phase 4
Completed
- Conditions
- Postoperative Bariatric Surgery
- First Posted Date
- 2008-02-06
- Last Posted Date
- 2011-01-24
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 140
- Registration Number
- NCT00608712
Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment
Phase 3
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2008-01-31
- Last Posted Date
- 2012-09-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 197
- Registration Number
- NCT00605267
- Locations
- 🇯🇵
Research Site, Osaka, Japan
Safety and Efficacy of Exenatide in Patients With Type 2 Diabetes Using a Thiazolidinedione or a Thiazolidinedione and Metformin
- First Posted Date
- 2008-01-29
- Last Posted Date
- 2015-04-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 165
- Registration Number
- NCT00603239
- Locations
- 🇿🇦
Research Site, Pretoria, South Africa
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
Phase 1
Active, not recruiting
- Conditions
- Breast NeoplasmsBreast CancerColon CancerColonic CancerKidney CancerColon NeoplasmsLung CancerMelanoma
- Interventions
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2025-05-06
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 140
- Registration Number
- NCT00600496
- Locations
- 🇺🇸
Research Site, Houston, Texas, United States
Comparison of the Subjective Well-being and Tolerability of Quetiapine XR to Risperidone
- First Posted Date
- 2008-01-25
- Last Posted Date
- 2012-10-05
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 798
- Registration Number
- NCT00600756
- Locations
- 🇹🇷
Research Site, Manisa, Turkey
A Phase 2, Double-Blind, Multiple-Dose Escalation Study to Evaluate NKTR-118 (Oral PEG-Naloxol) in Patients With Opioid-Induced Constipation (OIC)
- First Posted Date
- 2008-01-24
- Last Posted Date
- 2015-06-12
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 207
- Registration Number
- NCT00600119
- Locations
- 🇺🇸
Northwest Clinical Trials, Boise, Idaho, United States
🇺🇸Investigative Clinical Research of Indiana, LLC, Indianapolis, Indiana, United States
🇺🇸Pain & Rehabilitation Clinic of Chicago, Chicago, Illinois, United States
Quality of Life in Schizophrenic Patients
Completed
- Conditions
- Schizophrenia
- First Posted Date
- 2008-01-17
- Last Posted Date
- 2010-06-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 124
- Registration Number
- NCT00597168
- Locations
- 🇧🇪
Research Site, Woluwe-Saint-Lambert, Belgium
Long Term Study to Investigate the Efficacy & Safety of D961H (Esomeprazole) for the Prevention of NSAIDs-induced Ulcer
Phase 3
Completed
- Conditions
- Gastric UlcerDuodenal UlcerRheumatoid ArthritisOsteoarthritisLumbago
- Interventions
- First Posted Date
- 2008-01-16
- Last Posted Date
- 2012-09-14
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 395
- Registration Number
- NCT00595517
- Locations
- 🇯🇵
Research Site, Tokyo, Japan
A Phase-II Study Of TOMUDEX Plus Radiotherapy In Subject With Inoperable or Recurrent Rectal Cancer
Phase 2
Completed
- Conditions
- Inoperable or Recurrent Rectal Cancer
- First Posted Date
- 2008-01-10
- Last Posted Date
- 2008-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 49
- Registration Number
- NCT00590278
- Locations
- 🇹🇷
Research Site, Istanbul, Turkey
Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
Phase 4
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2008-01-10
- Last Posted Date
- 2008-01-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 125
- Registration Number
- NCT00590213
- Locations
- 🇹🇷
Research Site, Samsun, Turkey
© Copyright 2025. All Rights Reserved by MedPath